PharVision Advisers’s IMAX IMAX Stock Holding History

PharVision Advisers’s Portfolio IMAX Stock Details IMAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,510	Closed	-$462K	–	363
2025 Q4	$462K	Buy	+12,510	New	+$436K	0.23%	58

Other funds holding IMAX

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's IMAX Position: Q1 2026 in Review

PharVision Advisers sold out of IMAX (IMAX) in Q1 2026, closing a stake of 12,510 shares — an estimated $462K sold.

PharVision Advisers first reported a position in IMAX in Q4 2025 and held it in 1 quarter. The position peaked at $462K in Q4 2025. 254 funds tracked by Wall St. Rank hold IMAX as of Q1 2026.

PharVision Advisers reported no remaining IMAX position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 12,510 IMAX shares in Q1 2026, an estimated $462K.
PharVision Advisers first reported a position in IMAX in Q4 2025 and held it in 1 quarter.
PharVision Advisers's IMAX position peaked at $462K in Q4 2025.
254 funds tracked by Wall St. Rank held IMAX as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.